Benufutamab Biosimilar – Anti-TNFRSF10B, TRAILR2, CD262 mAb – Research Grade

Description of Benufutamab Biosimilar - Anti-TNFRSF10B, TRAILR2, CD262 mAb - Research Grade

Introduction:

Benufutamab Biosimilar, also known as Anti-TNFRSF10B, TRAILR2, CD262 monoclonal antibody (mAb), is a novel antibody-based therapy that targets the tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) or death receptor 5 (DR5). This biosimilar is a research grade monoclonal antibody with potential therapeutic applications in cancer treatment. In this article, we will provide a scientific description of Benufutamab Biosimilar, including its structure, activity, and potential applications.

Structure of Benufutamab Biosimilar:

Benufutamab Biosimilar is a fully humanized monoclonal antibody that is produced using recombinant DNA technology. It is a biosimilar of Benufutamab, which is a fully humanized monoclonal antibody developed by Amgen for the treatment of solid tumors. The biosimilar version has the same amino acid sequence and glycosylation pattern as the original antibody, making it highly similar in structure and function.

The antibody has a molecular weight of approximately 150 kDa and is composed of two identical heavy chains and two identical light chains. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of one constant domain (CL) and one variable domain (VL). The variable domains of both the heavy and light chains are responsible for binding to the target TNFRSF10B receptor.

Activity of Benufutamab Biosimilar:

Benufutamab Biosimilar is a potent inhibitor of the TNFRSF10B receptor, which is a member of the tumor necrosis factor (TNF) receptor superfamily. This receptor is expressed on the surface of various cancer cells and plays a crucial role in regulating cell survival and death. Benufutamab Biosimilar binds to the extracellular domain of TNFRSF10B, preventing its interaction with its ligand, TNF-related apoptosis-inducing ligand (TRAIL). This results in the inhibition of the TNFRSF10B signaling pathway, leading to the induction of apoptosis or programmed cell death in cancer cells.

Apart from its direct anti-tumor activity, Benufutamab Biosimilar also has immune-modulating effects. It can activate immune effector cells, such as natural killer (NK) cells and T cells, to target and kill cancer cells. This mechanism of action makes Benufutamab Biosimilar a promising therapy for the treatment of various solid tumors, including breast, lung, colon, and ovarian cancers.

Potential Applications of Benufutamab Biosimilar:

Benufutamab Biosimilar has shown promising results in preclinical studies, and it is currently being evaluated in clinical trials for the treatment of various types of cancer. It has the potential to be used as a monotherapy or in combination with other anti- cancer treatments, such as chemotherapy and immunotherapy.

One of the main advantages of Benufutamab Biosimilar is its high specificity for the TNFRSF10B receptor, which minimizes off-target effects and reduces the risk of toxicity. This makes it a safe and well-tolerated therapy, with minimal side effects reported in clinical trials.

Moreover, Benufutamab Biosimilar has the potential to overcome resistance to other anti- cancer treatments, such as chemotherapy and targeted therapies. This is because it targets a different pathway involved in cancer cell survival, making it a valuable addition to the current treatment options for cancer patients.

Conclusion:

In summary, Benufutamab Biosimilar is a novel monoclonal antibody that targets the TNFRSF10B receptor, a key player in cancer cell survival. Its structure, activity, and potential applications make it a promising therapy for the treatment of various solid tumors. With ongoing clinical trials, Benufutamab Biosimilar has the potential to become a valuable addition to the armamentarium of anti- cancer treatments.